At 2-year follow-up, the rates of endophthalmitis per injection(0.12%; p<0.01) and vitreous hemorrhage per injection (0.27%;p<0.01) were significantly higher in the anti-VEGF treatmentgroup. With Cox proportional hazards modeling, the anti-VEGFtreatment group had an 87.9% higher risk of severe ocular complicationsoverall, and a 2.6% increased risk per injection, both of whichwere statistically significant (p<0.01)

Conclusions:

Rates of endophthalmitis and vitreous hemorrhage were higherin the group treated with anti-VEGF injection than in the controlgroup, though nevertheless rare in both groups. The overallrisk of severe ocular complications was significantly higherin the anti-VEGF treatment group.